Heparin and low-molecular-weight heparin

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.

[1]  R. Collins,et al.  Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. , 1988, The New England journal of medicine.

[2]  M. Prins,et al.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.

[3]  D. Lane,et al.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. , 1984, The Biochemical journal.

[4]  K. Bauer.  Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. , 2002, American journal of orthopedics.

[5]  T. Barrowcliffe,et al.  Effects of Heparin Oligosaccharides with High Affinity for Antithrombin III in Experimental Venous Thrombosis , 1982, Thrombosis and Haemostasis.

[6]  A. Whittemore.  A randomized controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery: Turpie AGG, Levine MN, Hirsh J, et al. N Engl J Med 1986; 315: 925-9 , 1987 .

[7]  J. Durham.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis: Hull RD, Raskob GE, Pineo GF, et al. N Engl J Med 1992;326:975-82 , 1993 .

[8]  J. Hirsh,et al.  A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. , 1997, Blood.

[9]  T. Barrowcliffe,et al.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides. , 1987, Biochemical Journal.

[10]  T. Barrowcliffe,et al.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. , 1976, Thrombosis research.

[11]  P. Prandoni,et al.  Efficacy and Safety of a Low-Molecular-Weight Heparin and Standard Unfractionated Heparin for Prophylaxis of Postoperative Venous Thromboembolism: European Multicenter Trial , 1997, World Journal of Surgery.

[12]  V. Kakkar,et al.  Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. , 1972, Lancet.

[13]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[14]  J. Hirsh,et al.  Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. , 1991, Annals of internal medicine.

[15]  D. Waters,et al.  Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.

[16]  B. Meister,et al.  Comparison of low‐molecular‐weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia , 2008, Pediatric blood & cancer.

[17]  G. Wanner,et al.  Low molecular weight heparin-induced skin necrosis—a systematic review , 2005, Langenbeck's Archives of Surgery.

[18]  W. Owen,et al.  A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin. , 1978, Biochimica et biophysica acta.

[19]  P. de Moerloose,et al.  Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? No , 2004, Journal of thrombosis and haemostasis : JTH.

[20]  E. Castellet,et al.  Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double‐blind clinical trial , 2003, Journal of thrombosis and haemostasis : JTH.

[21]  S. Goodin,et al.  Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival , 2007, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[22]  A. Planès.  An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. , 2000, Seminars in thrombosis and hemostasis.

[23]  A. Planès.  Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  R. Rosenberg.  Actions and interactions of antithrombin and heparin. , 1975, The New England journal of medicine.

[25]  M. Samama,et al.  Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). , 2003, Thrombosis research.

[26]  M. Monreal,et al.  Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. , 1990, Haemostasis.

[27]  A. Turpie.  Antithrombotics and anticoagulants in coronary syndromes and stroke. , 2000, Seminars in thrombosis and hemostasis.

[28]  T. Barrowcliffe,et al.  Anticoagulant Activities of High and Low Molecular Weight Heparin Fractions , 1979, British journal of haematology.

[29]  H. Vinazzer,et al.  Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. , 1990, Thrombosis research.

[30]  O. Guilbaud,et al.  Low molecular weight heparin given the evening before surgery compared with conventional low‐dose heparin in prevention of thrombosis , 1988, The British journal of surgery.

[31]  J. Kelton,et al.  Heparin-induced thrombocytopenia. , 2007, Progress in hemostasis and thrombosis.

[32]  E. Bröcker,et al.  Tolerance to intravenous heparin in patients with delayed‐type hypersensitivity to heparins: a prospective study , 2005, British journal of haematology.

[33]  R. Kronmal,et al.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.

[34]  J. Hirsh,et al.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. , 1986, The New England journal of medicine.

[35]  G. Torri,et al.  Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations , 2001, Seminars in thrombosis and hemostasis.

[36]  L. Zacharski,et al.  Heparin and Cancer , 1998, Thrombosis and Haemostasis.

[37]  M. Scully,et al.  The acceleration of the inhibition of platelet prothrombinase complex by heparin. , 1986, The Biochemical journal.

[38]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.

[39]  J. Hopwood,et al.  Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin , 1976, FEBS letters.

[40]  M. Scully,et al.  The relative molecular mass dependence of the anti-factor Xa properties of heparin. , 1986, The Biochemical journal.

[41]  J. Vandenbroucke,et al.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis , 1992, The Lancet.

[42]  J. Harenberg.  Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes , 2004, Journal of thrombosis and haemostasis : JTH.

[43]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[44]  B. Mulloy,et al.  Characterization of Unfractionated Heparin: Comparison of Materials from the last 50 Years , 2000, Thrombosis and Haemostasis.

[45]  J. Hirsh,et al.  4 Clinical potential of low molecular weight heparins , 1990 .

[46]  T. Barrowcliffe,et al.  Standardization of Low Molecular Weight Heparins : A Collaborative Study , 1985, Thrombosis and Haemostasis.

[47]  R. Colman,et al.  Effect of Heparin on the Inhibition of the Contact System Enzymes , 1989, Annals of the New York Academy of Sciences.

[48]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[49]  J. Hirsh,et al.  Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. , 1996, The American journal of medicine.

[50]  E. Gurfinkel,et al.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. , 1995, Journal of the American College of Cardiology.

[51]  R. Aster,et al.  Heparin-induced thrombocytopenia associated with fondaparinux. , 2007, The New England journal of medicine.

[52]  T. Kirkwood,et al.  Four Heparin Preparations: Anti-Xa Potentiating Effect of Heparin after Subcutaneous Injection , 1976, Thrombosis and Haemostasis.

[53]  H. Hemker,et al.  Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths. , 2008, Thrombosis research.

[54]  B. Eriksson,et al.  Thrombosis prophylaxis with low molecular weight heparin in total hip replacement , 1988, The British journal of surgery.

[55]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[56]  E. Pritts,et al.  Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. , 2007, Gynecologic oncology.

[57]  M. Holmström,et al.  Comparison of Once-Daily Subcutaneous Fragmin® with Continuous Intravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[58]  J. Fiessinger.  Laboratory monitoring of low‐molecular‐weight heparin therapy , 2004, Journal of thrombosis and haemostasis : JTH.

[59]  T. Barrowcliffe,et al.  Anticoagulant Activities of Heparin and Fragments , 1989, Annals of the New York Academy of Sciences.

[60]  T. Barrowcliffe,et al.  A Collaborative Study Designed to Establish the 4th International Standard for Heparin , 1984, Thrombosis and Haemostasis.

[61]  M. Cohen.  Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. , 1999, Seminars in thrombosis and hemostasis.

[62]  A. Betz,et al.  Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. , 2001, Biochimica et Biophysica Acta.

[63]  T. Barrowcliffe,et al.  The Effect of Calcium Chloride on Anti-Xa Activity of Heparin and Its Molecular Weight Fractions , 1989, Thrombosis and Haemostasis.

[64]  B. Yalcin,et al.  Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer , 2007, Journal of surgical oncology.

[65]  H. Hemker,et al.  Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential , 1993, Thrombosis and Haemostasis.

[66]  D. Bergqvist,et al.  The effect of low molecular weight heparin on experimental thrombosis and haemostasis--the influence of production method. , 1987, Thrombosis research.

[67]  B. Boneu.  Laboratory monitoring of low‐molecular‐weight heparin therapy—part II , 2005, Journal of thrombosis and haemostasis : JTH.

[68]  C. Crafoord,et al.  HEPARIN AS A PROPHYLACTIC AGAINST THROMBOSIS , 1941 .

[69]  J. Hirsh,et al.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. , 1996, The New England journal of medicine.

[70]  R. Hull.  Treatment of pulmonary embolism: The use of low-molecularweight heparin in the inpatient and outpatient settings , 2008, Thrombosis and Haemostasis.

[71]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[72]  R. Wait,et al.  Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography , 1997, Thrombosis and Haemostasis.

[73]  M. Samama,et al.  Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis , 1988, The British journal of surgery.

[74]  C. Samama,et al.  A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer , 2006, Journal of thrombosis and haemostasis : JTH.

[75]  T. Barrowcliffe,et al.  An International Standard for Low Molecular Weight Heparin , 1988, Thrombosis and Haemostasis.

[76]  A. Khorana,et al.  A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment , 2007, Cancer.

[77]  D. W. Barritt,et al.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. , 1960, Lancet.

[78]  H. Messmore.  Clinical potential of low molecular weight heparins. , 1989, Seminars in thrombosis and hemostasis.

[79]  Low molecular weight heparin. , 1992 .

[80]  D. Bergqvist,et al.  Effects of Low Molecular Weight Heparin and Unfragmented Heparin on Induction of Osteoporosis in Rats , 1990, Thrombosis and Haemostasis.

[81]  J. Hirsh,et al.  The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate , 1985, British journal of haematology.

[82]  B. Boneu.  Low Molecular Weight Heparin Therapy: Is Monitoring Needed? , 1994, Thrombosis and Haemostasis.

[83]  M. Prins,et al.  For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? , 2000, Thrombosis research.

[84]  H. Hemker,et al.  The Mode of Action of Heparin in Plasma , 1988, Thrombosis and Haemostasis.

[85]  Rahul Raman,et al.  Glycomics approach to structure-function relationships of glycosaminoglycans. , 2006, Annual review of biomedical engineering.

[86]  H. Buller,et al.  Low-Molecular-Weight Heparins in the Treatment of Venous Thromboembolism , 1998, Annals of Internal Medicine.

[87]  T. Warkentin.  Heparin-induced thrombocytopenia. , 2018, Current hematology reports.

[88]  T. Barrowcliffe,et al.  Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. , 1984, Thrombosis research.

[89]  G. Nenci,et al.  Low molecular weight heparins: are they interchangeable? No , 2003, Journal of thrombosis and haemostasis : JTH.

[90]  C. Robinson-Cohen,et al.  The effect of anticoagulants on cancer risk and survival: systematic review. , 2007, Cancer treatment reviews.

[91]  M. Monreal,et al.  Heparin-Related Osteoporosis in Rats , 1990 .

[92]  D. Bergqvist,et al.  Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement. , 1988, Acta chirurgica Scandinavica. Supplementum.

[93]  J. Westwick,et al.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. , 1982, British medical journal.

[94]  M. Heizmann,et al.  Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions , 2007, Thrombosis and Haemostasis.

[95]  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. , 1992 .

[96]  T. Barrowcliffe,et al.  The Relative Antithrombotic Effectiveness of Heparin, a Low Molecular Weight Heparin, and a Pentasaccharide Fragment in an Animal Model , 1989, Thrombosis and Haemostasis.

[97]  H. Hemker,et al.  The Activity of Heparin in the Presence and Absence of Ca2+ Ions; why the Anti-Xa Activity of LMW Heparins Is about two Times Overestimated , 1993, Thrombosis and Haemostasis.

[98]  J. Boissel,et al.  Low molecular weight heparin in prevention of perioperative thrombosis. , 1992, BMJ.

[99]  F. Ofosu,et al.  Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma , 1994, Thrombosis and Haemostasis.

[100]  F. Largiadèr,et al.  Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. , 1986, Thrombosis and haemostasis.

[101]  J. Nunnelee.  Low-molecular-weight heparin. , 1997, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[102]  J. Hirsh,et al.  Low Molecular Weight Heparins (LMWH) in the Treatment of Patients with Acute Venous Thromboembolism , 1995, Thrombosis and Haemostasis.

[103]  K. Kurachi,et al.  The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. , 1981, The Biochemical journal.

[104]  R. Linhardt,et al.  Production and chemical processing of low molecular weight heparins. , 1999, Seminars in thrombosis and hemostasis.

[105]  M. Monreal,et al.  Fixed‐dose low‐molecular‐weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study , 2004, Journal of thrombosis and haemostasis : JTH.

[106]  B. Lobo,et al.  Fondaparinux for the treatment of patients with acute heparininduced thrombocytopenia , 2007, Thrombosis and Haemostasis.

[107]  E. Akl,et al.  Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. , 2007, The Cochrane database of systematic reviews.

[108]  J. Hirsh,et al.  Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. , 1989, The Biochemical journal.

[109]  R. Collins,et al.  Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin , 1989 .

[110]  J. Hirsh.  Laboratory monitoring of low‐molecular‐weight heparin therapy , 2004, Journal of Thrombosis and Haemostasis.

[111]  M. Prins,et al.  Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. , 1995, Archives of internal medicine.

[112]  H. Hemker,et al.  The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma , 1989, Thrombosis and Haemostasis.

[113]  M. Monreal,et al.  Comparison of Subcutaneous Unfractionated Heparin with a Low Molecular Weight Heparin (Fragmin®) in Patients with Venous Thromboembolism and Contraindications to Coumarin , 1994, Thrombosis and Haemostasis.

[114]  H. Hemker,et al.  The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif—the C‐domain , 2003, Journal of thrombosis and haemostasis : JTH.

[115]  B. Mulloy,et al.  A Collaborative Study to Establish the 5th International Standard for Unfractionated Heparin , 2000, Thrombosis and Haemostasis.

[116]  A. Planès,et al.  Prevention of Postoperative Venous Thrombosis: A Randomized Trial Comparing Unfractionated Heparin with Low Molecular Weight Heparin in Patients Undergoing Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[117]  V. Kakkar,et al.  Efficacy and safety of low‐molecular‐weight heparin (CY216) in preventing postoperative venous thrombo‐embolism: A co‐operative study , 1985, The British journal of surgery.

[118]  H. R. Büller,et al.  Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis , 2004 .

[119]  A. Planès,et al.  Comparison of two low‐molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[120]  O. Guilbaud,et al.  Low molecular weight heparin given the evening before surgery compared with conventional low‐dose heparin in prevention of thrombosis , 1988, The British journal of surgery.

[121]  U. Schmitz-Huebner,et al.  Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis , 1984, Klinische Wochenschrift.

[122]  F. Ofosu,et al.  Mechanisms of action of low molecular weight heparins and heparinoids. , 1990, Bailliere's clinical haematology.

[123]  J. Caen.  A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery , 1988, Thrombosis and Haemostasis.

[124]  M. Petitou,et al.  Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.

[125]  H. Hemker,et al.  The Mode of Action of Low Molecular Weight Heparin Preparation (PK10169) and Two of its Major Components on Thrombin Generation in Plasma , 1989, Thrombosis and Haemostasis.

[126]  V. Kakkar,et al.  Anticoagulant activities of four unfractionated and fractionated heparins. , 1978, Thrombosis research.

[127]  M. Laposata,et al.  College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. , 1998, Archives of pathology & laboratory medicine.

[128]  D. A. Lewis,et al.  Fondaparinux as a Treatment Option for Heparin‐Induced Thrombocytopenia , 2007, Pharmacotherapy.

[129]  U. Lindahl,et al.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. , 1980, Thrombosis research.

[130]  M. Rodger,et al.  The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials , 2007, Journal of thrombosis and haemostasis : JTH.

[131]  B. Lindblad,et al.  Low molecular weight heparin once daily compared with conventional low‐dose heparin twice daily. A prospective double‐blind multicentre trial on prevention of postoperative thrombosis , 1986, The British journal of surgery.

[132]  G. Simonneau,et al.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis , 1994, BMJ.

[133]  M. Cohen,et al.  The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy. , 2000, Thrombosis research.

[134]  M. Monreal.  Laboratory monitoring of low‐molecular‐weight heparin therapy—part II , 2005, Journal of thrombosis and haemostasis : JTH.

[135]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[136]  T. Heer,et al.  Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction , 2007, Thrombosis and Haemostasis.

[137]  M. Hoylaerts,et al.  Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III. , 1984, The Journal of biological chemistry.

[138]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.